Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Immunology

From Surviving to Thriving: Long-Term Well-Being with HAE

At a Glance

Modern management of Hereditary Angioedema (HAE) aims for total disease control and zero attacks. By using preventive medications and tracking progress with tools like the Angioedema Control Test, patients can significantly reduce attack anxiety and achieve a higher quality of life.

Living with Hereditary Angioedema (HAE) is no longer just about surviving the next attack. With modern medicine, the goal of care has shifted toward thriving—achieving a state of “total disease control” where the condition no longer dictates your daily choices [1][2].

Measuring Success Beyond Attack Counts

In the past, doctors mostly focused on how many attacks you had per month. Today, we use Patient-Reported Outcome Measures (PROMs) to get a fuller picture of your life [3].

The most important tool for you to know is the Angioedema Control Test (AECT) [3]. This is a simple four-question survey that helps you and your doctor objectively measure how well your treatment is working [3].

  • AECT Scoring: Higher scores indicate better control. A change of just 3 points in your score is considered a “meaningful difference” in your quality of life [4].
  • Total Control: Using the AECT alongside the HAE Quality of Life (HAE-QoL) questionnaire allows your team to adjust your medications until you reach a point where HAE has minimal impact on your well-being [3][5].

The Psychological Burden: Anticipatory Anxiety

Even if you haven’t had an attack in months, the “unpredictability” of HAE can lead to anticipatory anxiety—the constant fear of when the next swelling might occur [6][7]. This anxiety is a recognized part of the disease and is often linked to a lower quality of life, even in patients with infrequent attacks [8].

Modern long-term prevention (prophylaxis) can significantly lower this mental burden [9]. If anxiety remains high, it is a sign that your “Treat-to-Target” goal has not yet been met, and you should discuss additional support or treatment adjustments [1][10].

School and Workplace Accommodations

Because HAE is an “invisible illness” that causes unpredictable absences, navigating work or school can be incredibly stressful. You do not have to just push through it. Patients in the U.S. should explore workplace accommodations through the Family and Medical Leave Act (FMLA) to protect their job during unpredictable attack days. For children and college students, a 504 Plan can ensure they are not penalized for absences and have immediate access to the nurse for treatment administration. Work with your specialist to acquire the necessary letters of support.

Long-Term Safety of Modern Treatments

A major concern for many patients is whether taking medication every day or every month is safe over many years [11][12].

  • C1-INH Concentrates (IV or Subcutaneous): While generally safe and effective, there is a known risk of blood clots (thromboembolic events) associated with plasma-derived C1-inhibitors [13]. This risk is significantly higher if the drug is used at off-label high doses, or in patients with underlying risk factors like indwelling IV catheters or a history of thrombosis. If you have these risk factors, you must discuss them with your doctor and be actively monitored.
  • Monoclonal Antibodies (Lanadelumab): These are human-made proteins that are well-tolerated by both adults and adolescents [14][9]. The most common side effect is a minor reaction at the injection site [15].
  • Oral Kallikrein Inhibitors (Berotralstat): This daily pill is effective for long-term use [16][5]. Some patients experience mild stomach upset when starting the medication, but these symptoms are usually temporary [17][18].

By tracking your triggers, using tools like the AECT, and practicing self-administration, you take the power back from the disease [19][2]. You are moving toward a future where “zero attacks” is an expected outcome [1][10].

Return to Home Page

Common questions in this guide

What is the Angioedema Control Test (AECT)?
The AECT is a simple four-question survey used to measure how well your hereditary angioedema treatment is working. A higher score means better disease control, helping you and your doctor adjust medications to minimize the condition's impact on your daily life.
How can I manage the anxiety of waiting for an HAE attack?
Anticipatory anxiety is a common and recognized part of living with HAE, even if you haven't had an attack recently. Modern preventive treatments can significantly lower this mental burden by reducing attack frequency, but you should speak with your specialist if your anxiety remains high despite treatment.
Are long-term preventive treatments for HAE safe?
Modern preventive medications like C1-INH concentrates, lanadelumab, and berotralstat are generally safe and effective for long-term use. However, some treatments have specific risks, such as a potential for blood clots with high doses of plasma-derived C1-inhibitors, making ongoing medical monitoring essential.
Can I get workplace or school accommodations for HAE?
Yes, patients in the U.S. can use the Family and Medical Leave Act (FMLA) to protect their jobs during unpredictable HAE attacks. Children and students can utilize a 504 Plan to ensure they are not penalized for absences and can quickly access necessary medical care at school.
What is the 'Treat-to-Target' goal in HAE management?
The modern 'Treat-to-Target' goal aims for total disease control, where patients experience zero attacks and minimal disruption to their daily routines. Doctors work toward this goal by adjusting preventive therapies and tracking progress with quality of life surveys.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What should my target score be on the Angioedema Control Test (AECT), and how often should we reassess it?
  2. 2.Given my history, what is the safest long-term prophylactic option for me in terms of side effects?
  3. 3.If I am still experiencing 'attack anxiety' while on prevention, should we consider adjusting my dose or switching medications?
  4. 4.How can we work toward the 'Treat-to-Target' goal of zero attacks?
  5. 5.What documentation can your office provide to support my request for FMLA or a 504 plan at work or school?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    A Treat-to-Target approach in hereditary angioedema: expert consensus from a European committee.

    Cancian M, Caballero T, Boccon-Gibod I, et al.

    Frontiers in immunology 2026; (17()):1773279 doi:10.3389/fimmu.2026.1773279.

    PMID: 41766887
  2. 2

    Patient Preferences for Long-Term Prophylactic Treatment in Hereditary Angioedema: A Discrete-Choice Experiment.

    Villa KF, Mansfield C, Yarlas A, et al.

    The patient 2026; (19(3)):481-495 doi:10.1007/s40271-025-00798-8.

    PMID: 41565919
  3. 3

    Association Between the Angioedema Control Test and Attack Frequency in Hereditary Angioedema.

    Yarlas A, Feld AJ, Bjorner JB, et al.

    Clinical and translational allergy 2026; (16(1)):e70143 doi:10.1002/clt2.70143.

    PMID: 41525239
  4. 4

    Sensitivity to change and minimal clinically important difference of the angioedema control test.

    Fijen LM, Vera C, Buttgereit T, et al.

    Clinical and translational allergy 2023; (13(9)):e12295 doi:10.1002/clt2.12295.

    PMID: 37746798
  5. 5

    A Retrospective Analysis of Long-Term Prophylaxis with Berotralstat in Patients with Hereditary Angioedema and Acquired C1-Inhibitor Deficiency-Real-World Data.

    Johnson F, Stenzl A, Hofauer B, et al.

    Clinical reviews in allergy & immunology 2023; (65(3)):354-364 doi:10.1007/s12016-023-08972-2.

    PMID: 37914894
  6. 6

    The relationship between anxiety and quality of life in children with hereditary angioedema.

    Kessel A, Farkas H, Kivity S, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2017; (28(7)):692-698 doi:10.1111/pai.12758.

    PMID: 28692169
  7. 7

    Health-related quality of life among children with hereditary angioedema.

    Engel-Yeger B, Farkas H, Kivity S, et al.

    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology 2017; (28(4)):370-376 doi:10.1111/pai.12712.

    PMID: 28258590
  8. 8

    Quality of life and burden of disease in patients with hereditary angioedema and their caregivers.

    Levy DS, Nagase FI, Cheung A, et al.

    Allergy and asthma proceedings 2025; (46(5)):398-405 doi:10.2500/aap.2025.46.250048.

    PMID: 40958183
  9. 9

    Long-term prevention of hereditary angioedema attacks with lanadelumab in adolescents.

    Craig T, Tachdjian R, Bernstein JA, et al.

    Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology 2024; (133(6)):712-719.e1 doi:10.1016/j.anai.2024.08.001.

    PMID: 39128590
  10. 10

    Treatment Patterns and Characteristics of Patients with Hereditary Angioedema Treated with Lanadelumab: A US Retrospective Chart Review.

    Watt M, Chang R, Yu LH, et al.

    Drugs - real world outcomes 2025; (12(3)):351-365 doi:10.1007/s40801-025-00505-x.

    PMID: 40665203
  11. 11

    Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries.

    Guo Y, Zhang H, Lai H, et al.

    Orphanet journal of rare diseases 2022; (17(1)):399 doi:10.1186/s13023-022-02536-x.

    PMID: 36324138
  12. 12

    A safety review of prophylaxis drugs for adolescent patients with hereditary angioedema.

    Farkas H, Balla Z

    Expert opinion on drug safety 2023; (22(7)):549-561 doi:10.1080/14740338.2023.2226861.

    PMID: 37334624
  13. 13

    Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor.

    Farkas H, Kőhalmi KV, Veszeli N, et al.

    Allergy and asthma proceedings 2016; (37(2)):164-70 doi:10.2500/aap.2016.37.3933.

    PMID: 26802388
  14. 14

    A review of kallikrein inhibitor lanadelumab in hereditary angioedema.

    Hwang G, Johri A, Ng S, Craig T

    Immunotherapy 2019; (11(11)):937-944 doi:10.2217/imt-2018-0197.

    PMID: 31234673
  15. 15

    Hereditary Angioedema Prophylaxis Therapy: Berotralstat and Lanadelumab Safety Profile.

    Donadoni M, La Cava L, Bizzi E, et al.

    Medicina (Kaunas, Lithuania) 2025; (61(11)) doi:10.3390/medicina61111897.

    PMID: 41303734
  16. 16

    A review of berotralstat for the treatment of hereditary angioedema.

    Farkas H, Balla Z

    Expert review of clinical immunology 2023; (19(2)):145-153 doi:10.1080/1744666X.2023.2150611.

    PMID: 36408587
  17. 17

    Berotralstat in hereditary angioedema due to C1 inhibitor deficiency: first real-world evidence from a Canadian center.

    Srinivasan C, Ritchie B, Adatia A

    Frontiers in immunology 2024; (15()):1339421 doi:10.3389/fimmu.2024.1339421.

    PMID: 38318176
  18. 18

    Attack rate reductions following berotralstat initiation among US patients with hereditary angioedema in the real-world.

    Davis-Lorton M, Tachdjian R, Lopez-Gonzalez L, et al.

    Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology 2026; (22(1)).

    PMID: 41582175
  19. 19

    Hereditary angioedema: an update on causes, manifestations and treatment.

    Longhurst HJ, Bork K

    British journal of hospital medicine (London, England : 2005) 2019; (80(7)):391-398 doi:10.12968/hmed.2019.80.7.391.

    PMID: 31283393

This page discusses long-term management and quality of life for hereditary angioedema for educational purposes only. Always consult your immunology specialist before making changes to your treatment plan.

Get notified when new evidence is published on Hereditary angioedema.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.